• Rep. Katie Porter tore into Celgene CEO Mark Alles on Wednesday over price hikes on a cancer drug.
  • Porter grilled the CEOs of Teva, Celgene, and Bristol Myers Squibb as part of a House investigation into the pricing of Teva’s multiple-sclerosis drug Copaxone and Bristol Myers Squibb’s multiple-myeloma drug Revlimid.
  • During a Wednesday congressional hearing, Porter, a former consumer-protection attorney, used a whiteboard to illustrate points such as how much money the CEO made, how much a single pill of Revlimid cost over the years, and how much his bonus was as a result.
  • Alles confirmed that the manufacturing for the drug remained the same amid price increases but said the drug was approved for new uses.
  • “To recap here: The drug didn’t get any better, the cancer patients didn’t get any better — you just got better at making money, you just refined your skills at price gouging,” Porter replied.
  • Visit Business Insider’s homepage for more stories.

Rep. Katie Porter of California grilled Celgene CEO Mark Alles on Wednesday over price hikes on a cancer drug that she said resulted in a bonus of half a million dollars for the pharma executive.

Alles appeared before the House oversight committee alongside the CEOs of Teva and Bristol Myers Squibb as part of a House investigation into the pricing of Teva’s multiple-sclerosis drug Copaxone and Bristol Myers Squibb’s multiple-myeloma drug Revlimid. Alles served as CEO of Celgene before it was acquired by Bristol Myers Squibb in 2019.

“Since launching Revlimid in 2005, Celgene raised the price of the drug 22 times, from $215 per pill to $719 per pill,” according to documents from the House oversight committee’s chairwoman, Rep. Carolyn Maloney. “After Bristol Myers Squibb obtained the rights to Revlimid last November, it raised the price of Revlimid again, to $763